{"disease":{"id":"induce-anterograde-amnesia","name":"Induce Anterograde Amnesia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"diazepam","indication_name":"Induce Anterograde Amnesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valium","generic_name":"diazepam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"midazolam-hydrochloride","indication_name":"Induce Anterograde Amnesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Versed","generic_name":"Midazolam Hydrochloride","company_name":"Takeda Pharmaceutical Company Limited","drug_phase":"marketed","molecular_target":"GABA A receptor alpha-5/beta-2/gamma-2","drug_class":"Benzodiazepine","quality_score":58,"revenue":null,"mechanism":""},{"drug_id":"midazolam","indication_name":"Induce Anterograde Amnesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Versed","generic_name":"midazolam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Cytochrome P450 3A4, GABA A receptor alpha-3/beta-2/gamma-2","drug_class":"Benzodiazepine (short-acting)","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"lorazepam","indication_name":"Induce Anterograde Amnesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ativan","generic_name":"lorazepam","company_name":"Generic (originally Wyeth/Pfizer)","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-3/gamma-2, Fatty acid-binding protein, liver","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"diazepam","guideline_body":"FDA label","recommendation":"Not explicitly mentioned in the provided text.","line_of_therapy":"adj","evidence_grade":"C","guideline_year":null},{"drug_id":"diazepam","guideline_body":"FDA label","recommendation":"Not explicitly mentioned in the provided text.","line_of_therapy":"adj","evidence_grade":"C","guideline_year":null},{"drug_id":"diazepam","guideline_body":"FDA label","recommendation":"Not explicitly mentioned in the provided text.","line_of_therapy":"adj","evidence_grade":"C","guideline_year":null},{"drug_id":"diazepam","guideline_body":"FDA label","recommendation":"Not explicitly mentioned in the provided text.","line_of_therapy":"adj","evidence_grade":"C","guideline_year":null},{"drug_id":"diazepam","guideline_body":"FDA label","recommendation":"Not explicitly mentioned in the provided text.","line_of_therapy":"adj","evidence_grade":"C","guideline_year":null}],"source":"Drug Landscape verified database"}